ReviewJournal of cosmetic dermatology2022
Development of customized inner beauty products and customized cosmetics apps according to the use of NRF2 through DTC genetic testing after the COVID-19 pandemic.
Review in Journal of cosmetic dermatology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 11 citations in OpenAlex.
- Significance of nitrosative stress and glycoxidation products in the diagnosis of COVID-19.Scientific reports · 2024Article
- Redox Biomarkers - An Effective Tool for Diagnosing COVID-19 Patients and Convalescents.Journal of inflammation research · 2024Article
- Review
- Considering the risk of a coloring shampoo with the function of gray hair cover cosmetology and skin barrier: A systematic review.Health science reports · 2023Article
- Development of customized inner beauty products and customized cosmetics apps according to the use of NRF2 through DTC genetic testing after the COVID-19 pandemic.Journal of cosmetic dermatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAfter the coronavirus disease-19 (COVID-19) pandemic, the definition of health continuity, well-being, and well-dying is also evolving.
objectivesThis review is about the utilization of nuclear factor erythroid 2-related factor 2 (NRF2) for customized inner beauty products and customized cosmetics through Direct-To-Consumer (DTC) genetic testing in the non-face-to-face era that is evolving after the global pandemic.
methodsIn May 2021, we proposed a narrative review as a new report and commentary. It was written with reference to keywords such as "Covid DTC Genetic Test," "Covid 4th industrial revolution," "Covid NRF2," and "Antioxidants." This study was performed by searching on PubMed, Google Scholar, Scopus, and ResearchGate. A total of 432 papers were retrieved, of which 40 were successfully included in this study.
resultsWith the rapid transition to a non-face-to-face society after COVID-19, the concept of DTC was born, which allows consumers to receive genetic testing directly without visiting a medical institution. Based on the 4th industrial revolution, a convergence medical device is needed to secure the function as an NRF2 regulator of antioxidants in customized inner beauty products and customized cosmetics.
conclusionTherefore, let us look at the fact that a fusion medical device based on the 4th industrial revolution has emerged in the global DTC genetic test market, which is still insufficient to summarize important research results. This study is expected to be an important data for the development of antioxidants as NRF2 regulators in customized inner beauty products and customized cosmetics. As mobile use increases in the future, additional research focusing on app development is needed, and various follow-up studies are also needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.